Towards the era of biological biomarkers for Parkinson disease

Greene, F. L. & Sobin, L. H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J. Clin. 58, 180–190 (2008).

Article  Google Scholar 

Cardoso, F. et al. A statement of the MDS on biological definition, staging, and classification of Parkinson’s disease. Mov. Disord. https://doi.org/10.1002/mds.29683 (2023).

Article  Google Scholar 

Höglinger, G. U. et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191–204 (2024).

Article  Google Scholar 

Simuni, T. et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178–190 (2024).

Article  CAS  Google Scholar 

Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407–417 (2023).

Article  CAS  Google Scholar 

Miki, Y. et al. Clinical availability of skin biopsy in the diagnosis of Parkinson’s disease. Neurosci. Lett. 469, 357–359 (2010).

Article  CAS  Google Scholar 

Okuzumi, A. et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448–1455 (2023).

Article  CAS  Google Scholar 

Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020).

Article  CAS  Google Scholar 

Couto, B., Marras, C. & Di Luca, D. G. α-Synuclein seed amplification in Parkinson’s disease. Lancet Neurol. 22, 983–984 (2023).

Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif